Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Trial pipeline

Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.

Free access · No subscription for research tools or data exports

Filter the development pipeline

Reset

103 trials match this view; 141 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 6,703 across 103 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

201711
202122
202211
202333
20242020
20254141
20263535

Current indexed registry status

Recruiting103103

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Milestones to investigate

The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.

For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.

Matching trial records

103 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.

NCT06368492

Fibromyalgia
Maastricht University

NA

Recruiting

Registry updated 2025-09-15

35

ESTIMATED

2024-05-03
2025-12
2025-12
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms

NCT06160232

Severe Alcohol Use Disorder
Brugmann University Hospital

PHASE2

Recruiting

Registry updated 2024-08-07

62

ESTIMATED

2024-02-15
2025-12-15
2026-06-15
Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.

NCT06815653

Healthy
University College, London

PHASE1

Recruiting

Registry updated 2025-11-26

40

ESTIMATED

2025-03-01
2026-03
2026-12
Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus

NCT06378229

Treatment Resistant Depression
University Hospital, Ghent

PHASE2

Recruiting

Registry updated 2024-09-19

100

ESTIMATED

2024-05-21
2026-03
2026-12-31
Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.

NCT04882839

Obsessive-compulsive Disorder
Beersheva Mental Health Center

PHASE2

Recruiting

Registry updated 2025-11-19

15

ESTIMATED

2024-11-25
2026-06-01
2027-06-01
Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)

NCT06796361

Healthy
University Hospital, Basel, Switzerland

PHASE1

Recruiting

Registry updated 2025-05-28

16

ESTIMATED

2025-04-21
2026-08
2026-08
Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

NCT06731335

Chronic Neuropathic Pain · Pain Management
Unity Health Toronto

PHASE2

Recruiting

Registry updated 2025-03-30

30

ESTIMATED

2025-03-05
2026-08
2026-12
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)

NCT06899334

Healthy
University Hospital, Basel, Switzerland

PHASE1

Recruiting

Registry updated 2025-03-27

24

ESTIMATED

2025-04-01
2026-08-01
2026-08-01
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression

NCT06898606

Depressive Disorder
Federal University of Latin American Integration

PHASE1, PHASE2

Recruiting

Registry updated 2026-03-27

24

ESTIMATED

2024-09-05
2026-08-20
2026-11-20
Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study

NCT06798636

Self Harm
Imperial College London

EARLY_PHASE1

Recruiting

Registry updated 2025-12-05

30

ESTIMATED

2025-10-01
2026-08-31
2026-10-31
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study

NCT05585229

Opioid Dependence · Chronic Pain
University of British Columbia

PHASE2

Recruiting

Registry updated 2025-12-04

10

ESTIMATED

2025-10-27
2026-08-31
2026-08-31
Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer

NCT06001749

Opioid-Related Disorders · Pain Management · Pain Management and Care · Advanced Cancer · Advanced Cancers
Yvan Beaussant, MD, MSci

PHASE2

Recruiting

Registry updated 2026-08-05

15

ESTIMATED

2024-09-23
2026-10-01
2026-12-31
Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder

NCT06660381

Cannabis Use Disorder
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-03-18

12

ESTIMATED

2024-11-08
2026-11
2026-12
Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

NCT07079930

Healthy Volunteers
Hadassah Medical Organization

PHASE1

Recruiting

Registry updated 2026-02-05

10

ESTIMATED

2025-12-11
2026-11
2027-02
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission

NCT06430541

Breast Cancer · Ovarian Cancer
University of Colorado, Denver

PHASE1

Recruiting

Registry updated 2026-09-04

20

ESTIMATED

2024-11-21
2026-12
2028-12
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation

NCT04161066

Opioid Use Disorder
University of Wisconsin, Madison

PHASE1

Recruiting

Registry updated 2026-07-07

10

ESTIMATED

2021-01-13
2026-12
2026-12
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

NCT05452772

Tobacco Use Disorder
Johns Hopkins University

PHASE2

Recruiting

Registry updated 2026-06-29

66

ESTIMATED

2023-11-01
2026-12
2027-05
CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial

NCT06319378

MDD
Section for Affective Disorders; Northern Stockholm Psychiatry

PHASE2

Recruiting

Registry updated 2026-04-13

100

ESTIMATED

2024-04-19
2026-12
2026-12
Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder

NCT07737054

Post-Traumatic Stress Disorder, PTSD
Tel-Aviv Sourasky Medical Center

EARLY_PHASE1

Recruiting

Registry updated 2026-07-30

13

ESTIMATED

2025-07-22
2026-12-01
2026-12-31
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

NCT05301608

Healthy
Johns Hopkins University

PHASE1, PHASE2

Recruiting

Registry updated 2026-07-23

30

ESTIMATED

2022-03-03
2026-12-01
2027-01-01
The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

NCT06888128

PTSD
Baylor College of Medicine

PHASE2

Recruiting

Registry updated 2026-01-22

15

ESTIMATED

2025-01-30
2026-12-15
2026-12-15
Psilocybin and Affective Function in Chronic Lower Back Pain Depression

NCT06355414

Chronic Low-back Pain · Depression
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-04

40

ESTIMATED

2024-04-22
2026-12-30
2026-12-30
A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

NCT07072728

Adjustment Disorder · Adjustment Disorder With Anxious Mood · Cancer · Cancer Cachexia · Cancer of Endometrium · Cancer of Kidney · Cancer of Prostate · Cancer of the Breast · Cancer of Stomach · Cancer Melanoma Skin · Cancer Pancreas
Psyence Australia Pty Ltd

PHASE2

Recruiting

Registry updated 2026-03-03

87

ESTIMATED

2025-10-01
2026-12-30
2027-07-30
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

NCT06367738

Aging
University of California, Berkeley

PHASE1

Recruiting

Registry updated 2025-10-21

40

ESTIMATED

2025-11
2026-12-30
2027-12-30
TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT06200155

Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer
M.D. Anderson Cancer Center

PHASE2

Recruiting

Registry updated 2026-09-11

48

ESTIMATED

2024-04-16
2026-12-31
2026-12-31
Psilocybin-facilitated Treatment for Chronic Pain

NCT05068791

Fibromyalgia, Primary
University of Alabama at Birmingham

EARLY_PHASE1

Recruiting

Registry updated 2026-03-11

30

ESTIMATED

2023-11-01
2026-12-31
2026-12-31
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life

NCT05403086

Demoralization
Charles S. Grob, M.D.

PHASE2

Recruiting

Registry updated 2025-11-25

100

ESTIMATED

2025-01-19
2026-12-31
2027-12-31
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

NCT06160284

Opioid Use Disorder
Yale University

PHASE1

Recruiting

Registry updated 2026-07-07

12

ESTIMATED

2025-05-28
2027-01
2027-01
The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.

NCT06782724

COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD) · Atypical Parkinson Disease
University Medical Center Groningen

PHASE2

Recruiting

Registry updated 2026-05-08

108

ESTIMATED

2025-07-01
2027-01-01
2028-01-01
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer

NCT05398484

Advanced Cancer
NYU Langone Health

PHASE2, PHASE3

Recruiting

Registry updated 2025-12-04

200

ESTIMATED

2023-05-24
2027-01-01
2027-01-01
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

NCT06656702

Amyotrophic Lateral Sclerosis
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-08-11

24

ESTIMATED

2025-04-09
2027-01-30
2027-07-01
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

NCT07053917

Stroke · Chronic Stroke · Intracerebral Haemorrhage · Intracerebral Haemorrhage (ICH) · Intracerebral Hemorrhage Basal Ganglia · Ischemic Stroke · Ischemic Stroke and Hemorrhagic Stroke · Hemiparesis After Stroke · Hemiplegia Following Ischemic Stroke · Hemiplegia and Hemiparesis · Hemiplegia and/or Hemiparesis Following Stroke · Middle Cerebral Artery Stroke
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-02-13

20

ESTIMATED

2026-02-09
2027-02
2027-03
The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD

NCT07332143

PTSD
Emory University

PHASE2

Recruiting

Registry updated 2026-10-01

150

ESTIMATED

2026-06-08
2027-03
2027-03
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial

NCT06518720

Treatment Resistant Depression · Chronic Pain
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-07-30

16

ESTIMATED

2025-04-01
2027-03
2027-12
A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine

NCT06899594

Methamphetamine Use Disorder
Kevin Murnane

EARLY_PHASE1

Recruiting

Registry updated 2025-10-07

20

ESTIMATED

2025-04-04
2027-03
2027-03
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

NCT06801041

Depression · Anxiety · Cancer
M.D. Anderson Cancer Center

PHASE2

Recruiting

Registry updated 2026-08-12

20

ESTIMATED

2025-05-23
2027-03-31
2029-03-31
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

NCT06512220

Treatment Resistant Depression
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-07-30

12

ESTIMATED

2025-04-21
2027-04
2027-09
Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder

NCT06810310

Opioid Use Disorder
University of Pennsylvania

PHASE2

Recruiting

Registry updated 2026-07-09

24

ESTIMATED

2025-12-22
2027-05-01
2027-05-01
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

NCT07506395

PTSD
University of New Mexico

PHASE1

Recruiting

Registry updated 2026-05-22

36

ESTIMATED

2026-05-01
2027-05-01
2028-05-01
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293

Parkinson Disease · Depression
Joshua Woolley, MD, PhD

PHASE2

Recruiting

Registry updated 2026-08-07

60

ESTIMATED

2024-08-19
2027-06
2028-06
Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753

Psychedelic Effects in Healthy Volunteers
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-02-23

50

ESTIMATED

2025-02-05
2027-06
2027-12
A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?

NCT06786325

Opioid Use Disorder
Anna Rose Childress, Ph.D.

PHASE2

Recruiting

Registry updated 2025-10-29

36

ESTIMATED

2025-10-07
2027-06
2027-10
Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study

NCT06818994

Demoralization · Safety
Gustavo Vazquez

PHASE1

Recruiting

Registry updated 2026-03-18

15

ESTIMATED

2026-04-01
2027-06-01
2027-06-01
A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression

NCT07183748

Treatment Resistant Depression
Beersheva Mental Health Center

PHASE2

Recruiting

Registry updated 2025-11-19

20

ESTIMATED

2025-12-01
2027-06-01
2028-06-01
A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial

NCT06615908

Persisting Symptoms After Concussion
University of Calgary

PHASE1

Recruiting

Registry updated 2026-09-09

40

ESTIMATED

2025-05-27
2027-06-30
2027-12-30
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-09-04

20

ESTIMATED

2021-03-24
2027-06-30
2027-09-30
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT06706232

Bipolar II Disorder · Depression, Bipolar · Suicidality
The University of Texas Health Science Center, Houston

PHASE2

Recruiting

Registry updated 2026-08-12

10

ESTIMATED

2025-07-07
2027-08
2027-08
An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy

NCT06233344

Mental Health
University of Southern California

PHASE2

Recruiting

Registry updated 2026-08-06

40

ESTIMATED

2025-07-30
2027-08
2028-08
PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial

NCT07063862

Psychological Distress
Bruyère Health Research Institute.

PHASE3

Recruiting

Registry updated 2026-07-10

120

ESTIMATED

2026-01-28
2027-08
2027-09
Psilocybin-Assisted Therapy for Prolonged Grief

NCT06724289

Prolonged Grief Disorder
University of Virginia

EARLY_PHASE1

Recruiting

Registry updated 2026-06-23

12

ESTIMATED

2026-03-24
2027-08
2027-08
Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.

NCT07732166

Healthy Adults
Pontifícia Universidade Católica do Rio de Janeiro

EARLY_PHASE1

Recruiting

Registry updated 2026-07-28

100

ESTIMATED

2026-04-01
2027-08-01
2027-12-01
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

NCT05883540

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress
University Hospital, Basel, Switzerland

PHASE2

Recruiting

Registry updated 2026-04-29

60

ESTIMATED

2024-06-09
2027-09
2028-05
The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults

NCT07169747

Anorexia Nervosa
Region Skane

PHASE2

Recruiting

Registry updated 2026-08-14

40

ESTIMATED

2026-07-20
2027-10-01
2027-10-01
Psilocybin as a Treatment for Chronic Pain in Smokers

NCT07118332

Smokers With Chronic Pain
Yale University

EARLY_PHASE1

Recruiting

Registry updated 2026-08-03

10

ESTIMATED

2026-07-06
2027-10-01
2027-12-01
Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial

NCT05995769

Alcohol Use Disorder · Alcoholism
University of Calgary

PHASE2

Recruiting

Registry updated 2024-05-07

128

ESTIMATED

2024-03-20
2027-10-01
2027-10-01
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial

NCT07703722

Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Khyber Medical University Peshawar

PHASE3

Recruiting

Registry updated 2026-07-14

60

ESTIMATED

2026-04-01
2027-10-22
2027-11-22
Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)

NCT07216404

Lung Non-Small Cell Carcinoma · Unipolar Depression
Alan Davis

PHASE2

Recruiting

Registry updated 2026-05-14

10

ESTIMATED

2026-01-01
2027-10-31
2027-10-31
Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

NCT07818564

Phase I
Brown University

PHASE1

Recruiting

Registry updated 2026-10-08

24

ESTIMATED

2026-11
2027-11
2027-11
Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin

NCT05866471

Healthy · Psychedelic Experiences · Vagus Nerve Stimulation
University of Wisconsin, Madison

PHASE1

Recruiting

Registry updated 2026-07-29

108

ESTIMATED

2025-01-27
2027-11
2028-01
A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

NCT06902974

Post Traumatic Stress Disorder · PTSD
Sunstone Medical

PHASE2

Recruiting

Registry updated 2026-07-01

70

ESTIMATED

2026-05-23
2027-11
2028-05
2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers

NCT06626139

Healthy Participants With Lower-than-average Mental Well-being
Robin Carhart-Harris, PhD, MA

PHASE2

Recruiting

Registry updated 2026-06-04

120

ESTIMATED

2024-10-20
2027-11-30
2028-11-30
Psilocybin-Assisted Cognitive Behavioral Therapy for Depression

NCT07281352

Major Depressive Diorder
University of California, Los Angeles

PHASE1, PHASE2

Recruiting

Registry updated 2026-02-12

50

ESTIMATED

2026-01-05
2027-11-30
2027-11-30
The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults

NCT06768944

Investigating the Importance of the Subjective Psychedelic Experience
University of Calgary

PHASE2

Recruiting

Registry updated 2026-09-02

128

ESTIMATED

2026-05-15
2027-12
2028-01
Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

NCT06692192

Psilocybin
University of Wisconsin, Madison

PHASE1

Recruiting

Registry updated 2026-08-13

60

ESTIMATED

2025-08-07
2027-12
2027-12
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

NCT06442423

Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms · PTSD · Substance Use · Substance Use Disorder (SUD) · OCD
Yale University

PHASE1

Recruiting

Registry updated 2026-03-11

50

ESTIMATED

2024-10-17
2027-12
2027-12
Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial

NCT07048743

Caregiver Distress
University Health Network, Toronto

PHASE2

Recruiting

Registry updated 2026-06-23

15

ESTIMATED

2025-07-16
2027-12-02
2027-12-02
Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

NCT06988319

Chronic Pelvic Pain
Oregon Health and Science University

PHASE1

Recruiting

Registry updated 2026-09-23

15

ESTIMATED

2026-11-01
2027-12-31
2027-12-31
A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

NCT06969170

Generalized Anxiety Disorder (GAD)
Claudio N Soares

PHASE2

Recruiting

Registry updated 2026-08-12

50

ESTIMATED

2025-05-16
2027-12-31
2028-12-30
Mechanistic Studies of Psilocybin in Headache Disorders

NCT06464367

Migraine
Yale University

EARLY_PHASE1

Recruiting

Registry updated 2026-07-13

50

ESTIMATED

2025-05-19
2027-12-31
2027-12-31
A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

NCT07516405

Healthy Volunteer · Older Adults (65-85 Years)
University of Colorado, Denver

PHASE1

Recruiting

Registry updated 2026-09-16

40

ESTIMATED

2026-04-01
2028-03
2028-03
Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury

NCT07251491

Spinal Cord Injury · Depression - Major Depressive Disorder · Veteran
James J. Peters Veterans Affairs Medical Center

PHASE1, PHASE2

Recruiting

Registry updated 2026-08-10

30

ESTIMATED

2026-08-06
2028-03-01
2028-03-01
Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder

NCT06592833

Major Depressive Disorder
Icahn School of Medicine at Mount Sinai

PHASE2

Recruiting

Registry updated 2025-05-14

60

ESTIMATED

2025-02-25
2028-03-01
2028-03-01
Psilocybin vs Ketamine for Alcohol Use Disorder

NCT06405607

Alcohol Use Disorder · Alcohol Dependence · Alcohol Abuse
University of Iowa

PHASE2

Recruiting

Registry updated 2025-11-28

80

ESTIMATED

2025-06-12
2028-04
2028-04
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression

NCT06072898

Depressive Disorder · Major Depressive Disorder
Sunnybrook Health Sciences Centre

PHASE2

Recruiting

Registry updated 2026-03-30

50

ESTIMATED

2025-05-28
2028-05
2029-05
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial

NCT07490353

Depression - Major Depressive Disorder · Anhedonia
Medical University of Vienna

PHASE1

Recruiting

Registry updated 2026-03-24

85

ESTIMATED

2025-11-01
2028-05-31
2028-05-31
PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment

NCT07610135

Mood (Psychological Function) · Well Being · Mood · Healthy
Johns Hopkins University

PHASE1, PHASE2

Recruiting

Registry updated 2026-10-01

20

ESTIMATED

2026-10-30
2028-06
2028-12
PRoMiSS: Psilocybin and the Role of Music in Set and Setting

NCT07180108

Psilocybin · Music Intervention
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-15

100

ESTIMATED

2025-08-12
2028-06
2028-08
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]

NCT06814522

Burnout · Burnout, Healthcare Workers
University of California, San Diego

PHASE1, PHASE2

Recruiting

Registry updated 2026-09-02

30

ESTIMATED

2025-01-13
2028-06
2028-08
Psilocybin Administration With 5-HT1a Blockade

NCT07565493

Psychedelic Effects in Healthy Volunteers
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-09-14

18

ESTIMATED

2026-08-12
2028-06-15
2028-06-15
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839

Major Depressive Disorder
Sharmin Ghaznavi

PHASE3

Recruiting

Registry updated 2026-08-13

20

ESTIMATED

2024-09-10
2028-06-30
2028-06-30
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

NCT07211438

Treatment-Resistant Depression
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-08-21

40

ESTIMATED

2026-07-03
2028-07
2029-01
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

NCT06067737

Opioid Use Disorder
Johns Hopkins University

PHASE2

Recruiting

Registry updated 2026-07-17

90

ESTIMATED

2024-02-08
2028-07
2029-05
Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)

NCT06989957

Posttraumatic Stress Disorder
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-04

40

ESTIMATED

2025-09-17
2028-08
2029-08
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723

Depression · Anxiety · Major Depressive Disorder
Ohio State University

PHASE2

Recruiting

Registry updated 2026-07-23

40

ESTIMATED

2026-08-01
2028-09
2028-11
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT07570654

PTSD - Post Traumatic Stress Disorder · PTSD · PTSD Symptoms · PTSD, Post Traumatic Stress Disorder
COMPASS Pathways

PHASE2, PHASE3

Recruiting

Registry updated 2026-10-06

300

ESTIMATED

2026-09
2028-11
2029-09
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial

NCT06943573

Bipolar II Depression
Lakshmi N Yatham

PHASE2

Recruiting

Registry updated 2026-09-15

90

ESTIMATED

2026-06-15
2028-12
2028-12
A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

NCT07347405

Obsessive-Compulsive Disorder
Francisco A Moreno

PHASE1

Recruiting

Registry updated 2026-07-23

30

ESTIMATED

2026-05-18
2028-12-31
2029-01-31
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

NCT05265546

Perception Disorders
University of California, Berkeley

PHASE1

Recruiting

Registry updated 2026-07-10

80

ESTIMATED

2024-03-08
2028-12-31
2028-12-31
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment

NCT06796062

Opioid Use Disorder
NYU Langone Health

PHASE2

Recruiting

Registry updated 2026-01-23

480

ESTIMATED

2025-12-17
2029-02
2029-02
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

NCT06512194

Depression
Charles Raison

PHASE2

Recruiting

Registry updated 2026-08-10

141

ESTIMATED

2025-05-13
2029-05
2029-05
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

NCT06899165

Psychological Stress · Depression · Anxiety
Rachel Yehuda

PHASE2

Recruiting

Registry updated 2026-08-13

100

ESTIMATED

2026-08-28
2029-05-31
2030-01-02
A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)

NCT07104916

Post Traumatic Stress Disorder · Depression - Major Depressive Disorder
Anthony P King

PHASE2

Recruiting

Registry updated 2026-06-25

30

ESTIMATED

2026-07-01
2029-09
2029-12
Study of Psilocybin for Anorexia in Young Adults

NCT06399263

Anorexia Nervosa
Marissa Raymond-Flesch, MD, MPH

PHASE2

Recruiting

Registry updated 2026-03-03

40

ESTIMATED

2024-11-18
2029-11
2029-11
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

NCT07210112

Depression - Major Depressive Disorder · Treatment-resistant Depression (TRD)
Centre Hospitalier St Anne

PHASE2

Recruiting

Registry updated 2026-09-21

112

ESTIMATED

2026-06-30
2029-12-31
2030-06-30
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

NCT06132178

Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression · Depression
University of Texas at Austin

PHASE2

Recruiting

Registry updated 2025-11-26

100

ESTIMATED

2025-01-10
2029-12-31
2030-12-31
A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease

NCT07386730

Anhedonia in Healthy Volunteers · Older Adults (50-90 Years)
Jennifer Mitchell

PHASE1

Recruiting

Registry updated 2026-09-09

80

ESTIMATED

2026-06-01
2030-02
2030-02
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder

NCT06349083

Alcohol Use Disorder
NYU Langone Health

PHASE2

Recruiting

Registry updated 2026-09-02

200

ESTIMATED

2026-09-01
2030-05
2030-05
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

NCT07638553

Alcohol Use Disorder · Depressive Sympotoms · Psilocybin
Centre Hospitalier Universitaire de Nīmes

PHASE3

Recruiting

Registry updated 2026-07-01

172

ESTIMATED

2026-06-30
2030-06
2030-06
The Neurobiological Effect of 5-HT2AR Modulation

NCT03289949

Basic Science
Gitte Moos Knudsen

PHASE1

Recruiting

Registry updated 2024-12-16

200

ESTIMATED

2017-03-03
2030-06-01
2030-06-01
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369

Depression · Parkinson's Disease (PD)
Yale University

PHASE2

Recruiting

Registry updated 2026-09-28

40

ESTIMATED

2026-07-10
2030-07
2030-07
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia

NCT07607938

Anhedonia · Emotional Blunting
NYU Langone Health

PHASE1

Recruiting

Registry updated 2026-09-15

90

ESTIMATED

2026-09
2030-08-01
2030-09-30
A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans

NCT07226232

Major Depression
VA Office of Research and Development

PHASE3

Recruiting

Registry updated 2026-08-14

240

ESTIMATED

2026-08-03
2030-12-02
2031-06-30
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease

NCT07721467

Alzheimer's Disease
National Institute on Aging (NIA)

PHASE2

Recruiting

Registry updated 2026-10-08

200

ESTIMATED

2026-10-13
2030-12-31
2030-12-31

Reported research facilities

Brown University School of Public HealthProvidence, Rhode Island, United States
National Institute of Aging, Clinical Research UnitBaltimore, Maryland, United States
FLMiami, Florida, United States
FLOrlando, Florida, United States
ILChicago, Illinois, United States
MNEden Prairie, Minnesota, United States
NELincoln, Nebraska, United States
NVLas Vegas, Nevada, United States
NYNew York, New York, United States
BCNorth Vancouver, British Columbia, Canada
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States
Emory University HospitalAtlanta, Georgia, United States
Yale UniversityNew Haven, Connecticut, United States
Oregon Health & Science UniversityPortland, Oregon, United States
GHU Paris Psychiatrie and NeurosciencesParis, France
University of California San Francisco (UCSF) Department of NeurologySan Francisco, California, United States
University of Colorado Anschutz Medical CampusAurora, Colorado, United States
Emory University Brain Health CenterAtlanta, Georgia, United States
Dana-Farber Cancer InstituteBoston, Massachusetts, United States
University of Nebraska Medical CenterOmaha, Nebraska, United States
New York University Langone Health, Center for Psychedelic MedicineNew York, New York, United States
Center for Psychedelics and Consciousness Research in the Behavioral Biology Research CenterBaltimore, Maryland, United States
NYU Langone HealthNew York, New York, United States
Djavad Mowafaghian Centre for Brain HealthVancouver, British Columbia, Canada
Department of Psychiatry, University of Ottawa, The Ottawa HospitalOttawa, Ontario, Canada
Department of Psychiatry, University of Toronto, University Health Network,Toronto, Ontario, Canada
Center for Psychedelics and Consciousness ResearchBaltimore, Maryland, United States
MD Anderson Cancer CenterHouston, Texas, United States
University of CalgaryCalgary, Alberta, Canada
University of California San Francisco, Sandler Neuroscience BuildingSan Francisco, California, United States
Johns Hopkins University School of MedicineBaltimore, Maryland, United States
Outpatient CTRCAurora, Colorado, United States
University of Colorado Cancer CenterAurora, Colorado, United States
UC San DiegoSan Diego, California, United States
Toronto Western Hospital (University Health Network)Toronto, Ontario, Canada
Centre for Addiction and Mental HealthToronto, Ontario, Canada
Psykiatrikliniken, Baravägen 1Lund, Sweden
Birmingham VA Medical Center, Birmingham, ALBirmingham, Alabama, United States
Tuscaloosa VA Medical Center, Tuscaloosa, ALTuscaloosa, Alabama, United States
VA Portland Health Care System, Portland, ORPortland, Oregon, United States
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, Pennsylvania, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, Washington, United States
UW School of Medicine and Public HealthMadison, Wisconsin, United States
The Parsons Research Center for Psychedelic HealingNew York, New York, United States
Athinoula A. Martinos Center for Biomedical ImagingCharlestown, Massachusetts, United States
The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States
The University of Texas Health Science Center at HoustonHouston, Texas, United States
Kingston General Health Research InstituteKingston, Ontario, Canada
Vail Health Behavioral HealthEdwards, Colorado, United States
James J. Peters Department of Veterans Affairs Medical CenterThe Bronx, New York, United States
University of California, San FranciscoSan Francisco, California, United States
Univeristy of Southern California Brain and Creativity InstituteLos Angeles, California, United States
Department of Veterans AffairsWest Haven, Connecticut, United States
Tel Aviv Sourasky Medical CenterTel Aviv, Israel
University of Wisconsin - MadisonMadison, Wisconsin, United States
Centro de Pesquisas Matteo RicciRio de Janeiro, Rio de Janeiro, Brazil
The Clinical and Translational Sciences Research CenterTucson, Arizona, United States
The Ohio State University Department of PsychiatryColumbus, Ohio, United States
Institute of Health Science, Khyber Medical UniversityIslamabad, Capital, Pakistan
Hayatabad Medical Complex PeshawarPeshawar, KPK, Pakistan
Khyber Medical UniversityPeshawar, KPK, Pakistan
VA Connecticut Healthcare SystemWest Haven, Connecticut, United States
William Osler Health SystemBrampton, Ontario, Canada
Providence Care HospitalKingston, Ontario, Canada
St. Joseph's HealthcareLondon, Ontario, Canada
South Lake Regional Health CentreNewmarket, Ontario, Canada
Bruyere HealthOttawa, Ontario, Canada
The Ottawa HospitalOttawa, Ontario, Canada
McGill University Health CentreMontreal, Quebec, Canada
University of California, BerkeleyBerkeley, California, United States
University of PennsylvaniaPhiladelphia, Pennsylvania, United States
University of WisconsinMadison, Wisconsin, United States
Centre Hospitalier de la Côte BasqueBayonne, France
CHU BesançonBesançon, France
CHU de BordeauxBordeaux, France
CHU BrestBrest, France
CH Le VinatierBron, France
CHU de NantesNantes, France
CHU de NîmesNîmes, France
CHU Saint-EtienneSaint-Priest, France
Sunstone Medical, PCRockville, Maryland, United States
University of Alabama at BirminghamBirmingham, Alabama, United States
New York UniversityNew York, New York, United States
The Ohio State University Medical CenterColumbus, Ohio, United States
Toronto General HospitalToronto, Ontario, Canada
University of VirginiaCharlottesville, Virginia, United States
UCSF Mission BaySan Francisco, California, United States
Interdisciplinary Substance Use and Brain Injury (ISUBI)Albuquerque, New Mexico, United States
Ohio State University Comprehensive Cancer CenterColumbus, Ohio, United States
National Institute of Mental HealthPrague, Czechia
Bispebjerg HospitalCopenhagen, Denmark
University Medical Center GroningenGroningen, Provincie Groningen, Netherlands
Champalimaud FoundationLisbon, Portugal
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland
Spital Uster AG, Division of Internal MedicineUster, Switzerland
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland
region Västra GötalandGothenburg, Göteborg, Sweden
Norra Stockholms PsykiatriStockholm, Stockholm County, Sweden
Psykiatriska Kliniken, Akademiska SjukhusetUppsala, Uppsala County, Sweden
Örebro sjukhusÖrebro, Örebro County, Sweden
Sunnybrook Health Sciences CentreToronto, Ontario, Canada
Federal University of Latin American IntegrationFoz do Iguaçu, Paraná, Brazil
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General PsychiatryVienna, State of Vienna, Austria
Queen's UniversityKingston, Ontario, Canada
UAB Beacon TowerBirmingham, Alabama, United States
Connecticut Mental Health Center - Yale School of MedicineNew Haven, Connecticut, United States
Mind Medicine Australia ClinicAbbotsford, Victoria, Australia
Paratus Clinical Research MelbourneNorthcote, Victoria, Australia
Empax CentreLeederville, Western Australia, Australia
Johns HopkinsBaltimore, Maryland, United States
UCLA Semel InstituteLos Angeles, California, United States
Hadassah Medical Organization, Jerusalem, IsraelJerusalem, Israel
Duke City Recovery ToolboxAlbuquerque, New Mexico, United States
University of New MexicoAlbuquerque, New Mexico, United States
StartCareBrooklyn, New York, United States
VIP Community Services, IncThe Bronx, New York, United States
Baylor College of MedicineHouston, Texas, United States
Imperial College LondonLondon, United Kingdom
University of British Columbia - Okanagan CampusKelowna, British Columbia, Canada
University of Colorado Anschutz Medical campus (CU AMC)Aurora, Colorado, United States
University of Iowa Health CareIowa City, Iowa, United States
University College LondonLondon, United Kingdom
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600Austin, Texas, United States
Marin Cancer CareGreenbrae, California, United States
University of California, Los AngelesLos Angeles, California, United States
University of San FranciscoSan Francisco, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, California, United States
Sunstone TherapiesRockville, Maryland, United States
Mental Health Center Beer ShevaBeersheba, Israel
Beer Sheva Mental Health CenterBeersheba, Israel
LSU Health ShreveportShreveport, Louisiana, United States
Maastricht UniversityMaastricht, Limburg, Netherlands
Leiden University Medical CenterLeiden, South Holland, Netherlands
Clinical Trial UnitBasel, Canton of Basel-City, Switzerland
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy ResearchNew York, New York, United States
St. Michael's Hospital. Unity Health TorontoToronto, Ontario, Canada
University HospitalBasel, Switzerland
Neurobiology Research Unit, RigshospitaletCopenhagen, Denmark
Ghent University HospitalGhent, Oost-Vlaanderen, Belgium
Brugmann University HospitalBrussels, Belgium

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.